Janus Capital Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 0.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,418,861 shares of the biopharmaceutical company’s stock after buying an additional 26,690 shares during the period. Janus Capital Management LLC’s holdings in ACADIA Pharmaceuticals were worth $117,539,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ACAD. Envestnet Asset Management Inc. raised its position in ACADIA Pharmaceuticals by 23.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 617 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in ACADIA Pharmaceuticals during the fourth quarter worth about $145,000. PNC Financial Services Group Inc. increased its stake in ACADIA Pharmaceuticals by 138.8% in the first quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 2,548 shares during the period. Nisa Investment Advisors LLC increased its stake in ACADIA Pharmaceuticals by 12.8% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 510 shares during the period. Finally, Oppenheimer Asset Management Inc. bought a new stake in ACADIA Pharmaceuticals during the first quarter worth about $161,000. Institutional investors own 97.19% of the company’s stock.

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Shares of ACADIA Pharmaceuticals Inc. (ACAD) traded up 1.95% during midday trading on Friday, hitting $29.24. 1,382,331 shares of the company’s stock were exchanged. ACADIA Pharmaceuticals Inc. has a 1-year low of $20.68 and a 1-year high of $40.83. The stock’s 50 day moving average is $28.10 and its 200-day moving average is $32.03. The stock’s market cap is $3.57 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.01. The company had revenue of $15.30 million for the quarter, compared to analyst estimates of $15.17 million. ACADIA Pharmaceuticals had a negative net margin of 948.93% and a negative return on equity of 63.07%. During the same quarter last year, the firm posted ($0.45) earnings per share. Analysts predict that ACADIA Pharmaceuticals Inc. will post ($2.83) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Janus Capital Management LLC Increases Position in ACADIA Pharmaceuticals Inc. (ACAD)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/06/23/janus-capital-management-llc-increases-position-in-acadia-pharmaceuticals-inc-acad.html.

ACAD has been the topic of several recent research reports. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $49.00 target price on shares of ACADIA Pharmaceuticals in a research note on Wednesday, April 5th. Rodman & Renshaw reaffirmed a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. Vetr downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating and set a $41.20 target price on the stock. in a research note on Monday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, May 10th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $42.88.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.